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COMMENTARY
ONLINE FIRST
Mandatory HPV Vaccination
and Political Debate
Lawrence O. Gostin, JD
VACCINATIONS ARE AMONG THE MOST COST-effective and widely used public health interven-tions but have provoked popular resistance, withcompulsory vaccination framed as an unwarranted
state interference. When the US Food and Drug Administra-
tion (FDA) approved a human papillomavirus (HPV) vac-
cine in 2006, conservative religious groups strongly opposed
a mandate, arguing it would condone premarital sex and un-
dermine parental rights. Yet Governor Rick Perry signed an
executive order in 2007 making Texas the first state to enact
a mandate—later revoked by the state legislature.
Mandatory HPV vaccination received additional atten-
tion during a recent debate among Republican presidential
candidates.Michele Bachmann, US representative fromMin-
nesota, Rick Santorum, former US senator from Pennsyl-
vania, andGovernor Perry had spirited exchanges about the
executive order that Perry issued in 2007. Bachmann called
the vaccine “a dangerous drug” and Santorum added, “There
is no government purpose served for having little girls in-
oculated at the force and compulsion of the government.”
Perry almost immediately disavowed his action, saying first
that the vehicle of an executive order was wrong and then
that vaccination should be “opt-in.”1
Comments such as these could cause parents to decide not
to have their children vaccinated, thereby potentially leading
to preventable illness and perhaps even death. The scientific
evidence demonstrates that population-based HPV vaccina-
tion is safe and effective, justifyingwidespread adoption of the
vaccine. The question is whether a state mandate would in-
crease vaccination rates or result in a backlashnot only against
HPVvaccinationbut alsowider childhoodvaccinations.Given
the political divisiveness, states should launch health educa-
tion campaigns before resorting to compulsion.
HPV Vaccine Effectiveness and Safety
Human papillomavirus infection and HPV-associated can-
cers pose a major public health threat. Human papilloma-
virus is the most common sexually transmitted infection in
the United States, with an estimated 20 million individuals
currently infected and 6.2 million newly infected annu-
ally.2 The HPV prevalence among girls and women is 26.8%
overall, with increasing prevalence each year from ages 14
to 24 years (44.8% for ages 20-24 years), followed by a
gradual decline through age 59 years; high-risk HPV types
are detected in only 3.4% of women tested.2
Nononcogenic HPV types 6 and 11 are associated with
genital warts and recurrent respiratory papillomatosis. High-
risk HPV types are detected in virtually all cervical, vagi-
nal, and vulvar cancers in women, and HPV types 16 and
18 are associated with 70% of cervical cancers. Each year,
more than 12 000 new cervical cancer cases are diagnosed
in the United States, with more than 4000 deaths from cer-
vical cancer occurring annually.3 Humanpapillomavirus also
is associated with cancer of the penis, as well as cancers of
the oropharynx and anus in both women and men. Per-
sons with lower education and higher poverty experience
disproportionate burdens of HPV-associated cancers.
In June 2006, the FDA licensed a prophylactic quadriva-
lent HPV vaccine against HPV types 6, 11, 16, and 18 for
use among girls and women aged 9 to 26 years.4 In October
2009, the FDAapproved a bivalent vaccine againstHPV types
16 and 18.5 TheAdvisoryCommittee on Immunization Prac-
tices (ACIP) recommends routine quadrivalent or bivalent
vaccination of girls aged 11 or 12 years with 3 doses that
can start at age 9 years. The ACIP recommends “catch-up”
vaccination for girls and women aged 13 to 26 years who
have not been previously vaccinated. Quadrivalent HPV vac-
cinemay be given to boys and men aged 9 to 26 years.6 Ide-
ally, vaccination should begin before sexual activity.
Numerous public health organizations including the Cen-
ters for Disease Control and Prevention, the American Acad-
emy of Pediatrics, and theAmericanAcademy of Family Phy-
sicians endorseHPVvaccination for youngwomen.Although
clinical trial evidence has not demonstrated prevention of in-
vasive cervical cancer fromHPVvaccination, it has shown that
the vaccine is almost 100% effective in preventing infections
associated with HPV types included in the vaccine.
TheHPVvaccinehasan impressivesafetyprofile.More than
29000male and female individuals have participated in qua-
drivalentvaccinetrials,morethan30000girlsandwomenhave
participated inbivalentvaccine trials, andanestimated35mil-
lionvaccinedoseshavebeenadministered in theUnitedStates.
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Adverseeffectswereminorandsimilartothosefoundwithmost
vaccines,suchasdizziness, fainting,andinjectionsitereactions.
Serioussystemicadversereactionsarerareandcertainlydonot
include mental retardation as Bachmann implied. As of June
22,2011, theVaccineAdverseEventReportingSystemhadnot
confirmedseriousadverseeffectsgreaterthanbackgroundrates.7
Are State Mandates Effective?
Although 41 states have introduced legislation related toHPV
vaccine, onlyTexas (revoked),Virginia, and theDistrict ofCo-
lumbiahave enactedHPVvaccinemandates. BothVirginia and
the District of Columbia offer generous “opt-outs” at par-
ents’ “discretion.” Yet 20 states have laws to fund vaccines or
educate the public, and health departments in New Hamp-
shire, South Dakota, and Washington distribute free vac-
cines.8 Since research on the effectiveness of mandates is un-
available, the critical question is whether state laws actually
increase vaccination rates. The kind of mandate also must be
considered, as generous “opt-outs” may mean little positive
effect. However,mandatesmay be premature because of drug
company lobbying, public backlash, gender equity, and cost.
DrugCompany Lobbying. Following FDA approval of the
quadrivalent vaccine, the manufacturer (Merck) lobbied for
compulsory vaccination laws. During the Republican debate,
Governor Perry deniedMerck’s political influence, stating that
he received only $5000. However,Merck donated $28 500 to
his gubernatorial campaign and an additional $377500 to the
RepublicanGovernors Association, forwhich Perry served as
chairman.1 Furthermore, Merck’s lobbyist at the time of the
executive order was Governor Perry’s former chief of staff.
Merck’s lobbying is concerning and fuels public distrust of law-
makers’ objectivity in enacting compulsory vaccination.
Public Backlash.There are special reasonsHPVmandates
mightprovokeapublicbacklash,withacombinationofsocially
divisive implications—adolescentsex,bodily integrity,andpa-
rental responsibility. There is no evidence that HPV vaccines
increase sexual activity among adolescents, but this aspect of
mandatoryvaccination isapoliticalhotbutton.Statemandates
override parental consent, fueling long-standing antivaccina-
tionmovements.Moreover,HPVvaccination isdifferent than
most diseaseswarranting compulsionbecause the virus is not
airborne and does not pose immediate risks of transmission
throughcasual contact amongadolescents, suchas in schools.
Gender Equity. Although the ACIP permits male HPV
vaccination, government recommendations are directed
solely toward young women. The HPV vaccine is the first
mandated for only 1 gender. Yetmen have equally highHPV
rates and are as likely to transmit the infection to partners.
Men are at risk of virus-associated warts and cancers. Re-
ducingHPV prevalence amongmenwill also decrease trans-
mission of HPV infection to women. Although gender dis-
tinctions are justified by differences in available data, lack
of gender equity remains ethically troubling. Is it fair if young
girls are compelled to submit to a new vaccine as a condi-
tion of publicly funded education when boys are not?
Cost.TheHPVvaccineisamongthemostcostly,withaprice
of $360 for 3 doses.9 At the same time, HPV-related diseases
areestimatedtocostat least$4billionindirectmedicalexpenses
(not including lost productivity) annually.9 Whowill pay for
mandatedHPVvaccinesandwhatotherpublichealth services
would society have to forego? State health departments have
decreasing budgets with expanded missions. Physicians also
mustpay forvaccinesandwait forprivateorpublic reimburse-
ment, placing further strain on the health care system.
Human papillomavirus vaccination rates lag far behind
other adolescent vaccinations, increasing to only 32% in
2010.10 Government should implement a well-funded cam-
paign to increase HPV vaccination rates as part of a com-
prehensive sexually transmitted infection prevention pack-
age: pay for the vaccine or require public or private coverage;
launch health education and social marketing campaigns;
and reduce associated harms through early screening and
treatment. If voluntary vaccinationproves unsuccessful, states
should seriously consider compulsory vaccination lawswith-
out generous exemptions. For now,maintaining public trust
is vital both for HPV vaccination and for the viability of
school-based vaccination programs. Above all, health policy
must be driven by science. Political leaders have a moral re-
sponsibility to ensure their political advocacy is well in-
formed and does not cause future harm to America’s youth.
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